Plus Therapeutics secures UnitedHealthcare coverage for brain cancer test

Go back to Plus Therapeutics secures UnitedHealthcare coverage for brain cancer test

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

September 25, 2025 7:30 AM EDT

HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics,... More